59 results
POS AM
SPRC
SciSparc Ltd
2 May 24
Prospectus update (post-effective amendment)
5:17pm
dates of our anticipated clinical trials;
our assessment of the potential of our pharmaceutical product candidates to treat certain indications;
our
425
SPRC
SciSparc Ltd
2 May 24
Business combination disclosure
4:46pm
of asset impairment and performed an asset impairment assessment, in accordance with the requirements of International Accounting Standard IAS 36 … the methodology used in determining the refundable amount; assessment of the skills, experience and independence of the valuer on behalf of the company’s
6-K
EX-99.1
SPRC
SciSparc Ltd
2 May 24
Consolidated Financial Statements as for Consolidated Financial Statements as for To the shareholders of
4:02pm
of Notes 2(12) and 2(15), the company identified signs of asset impairment and performed an asset impairment assessment, in accordance … of the identification of the cash generating units; Examining the methodology used in determining the refundable amount; assessment of the skills, experience
20-F/A
2023 FY
SPRC
SciSparc Ltd
2 May 24
Annual report (foreign) (amended)
9:18am
revenue, operating expenses, and uses and sources of cash used in management’s assessment of whether the Company has sufficient liquidity to fund operations
425
SPRC
SciSparc Ltd
12 Apr 24
Business combination disclosure
9:23am
limitation period with respect to any claim or assessment for any income or other material Taxes (other than pursuant to an extension of time to file any Tax … or consent to any extension or waiver of any limitation period with respect to any claim or assessment for any income or other material Taxes (other than
6-K
EX-99.1
ajbj5es
11 Apr 24
Agreement and Plan of Merger
4:05pm
F-1
c5z ytx5voz7cuxx
27 Feb 24
Registration statement (foreign)
4:15pm
F-3/A
9l9m9gyc
20 Nov 23
Shelf registration (foreign) (amended)
4:22pm
F-3
el6wxs kta
3 Nov 23
Shelf registration (foreign)
4:06pm
6-K
EX-99.2
7l6d7tez7h7eti9z
16 Oct 23
Interim Consolidated Financial Statements
5:00pm
6-K
EX-10.1
jah7osa u0
12 Oct 23
SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
8:48am
6-K
EX-1.1
hkrv1g
14 Aug 23
SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
4:31pm
424B5
dg1d 7tbu
14 Aug 23
Prospectus supplement for primary offering
9:14am
424B3
nkdxzvbb qr81i55xz
10 Aug 23
Prospectus supplement
6:32am
6-K
EX-99.1
oxr34 sie4xx
16 May 23
At-The-Market Issuance Sales Agreement
8:06pm
6-K
EX-99.1
spv3qqi782o
2 May 23
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer’s Disease and Agitation
7:28am
6-K
EX-99.2
3c2abi74h3v51fd6urxw
29 Dec 22
Interim Consolidated Financial Statements
4:03pm
6-K
EX-99.1
czfch0
8 Nov 22
SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation
7:33am